Genomic profiling of malignant melanoma using tiling-resolution arrayCGH

Oncogene

Volumn 26, Issue 32, 2007, Pages 4738-4748

  Jonsson G ^a   Dahl, C ^b   Staaf, J ^a   Sandberg, T ^a   Bendahl, P O ^a   Ringner M ^c   Guldberg, P ^b   Borg, A ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

ArrayCGH; Melanoma; Mutation

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2 A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER CELL CULTURE; CHROMOSOME 15Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 20; CHROMOSOME 20Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MAPPING; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; MELANOMA; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SKIN CARCINOGENESIS;

CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; GENE AMPLIFICATION; GENE DOSAGE; GENES, NEOPLASM; GENOMICS; HUMANS; MELANOMA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SKIN NEOPLASMS;

BACTERIA (MICROORGANISMS);

EID: 34447515273     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210252     Document Type: Article

References (38)

1. Autio R, Hautaniemi S, Kauraniemi P, Yli-Harja O, Astola J, Wolf M et al. (2003). CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics 19: 1714-1715.
2. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540.
3. Cachia AR, Indsto JO, McLaren KM, Mann GJ, Arends MJ. (2000). CDKN 2A mutation and deletion status in thin and thick primary melanoma. Clin Cancer Res 6: 3511-3515.
4. Carreira S, Liu B, Goding CR. (2000). The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J Biol Chem 275: 21920-21927.
5. Christensen C, Guldberg P. (2005). Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 24: 6292-6302.
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147.
7. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D et al. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23: 5968-5977.
8. Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D et al. (2003). Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73: 301-313.
9. Grafstrom E, Egyhazi S, Ringborg U, Hansson J, Platz A. (2005). Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res 11: 2991-2997.
10. Gronbaek K, de Nully Brown P, Moller MB, Nedergaard T, Ralfkiaer E, Holler P et al. (2000). Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 14: 1727-1735.
11. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. (1997a). Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 9: 348-355.
12. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. (1997b). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660-3663.
13. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL et al. (2005). The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102: 6092-6997.
14. Hayward NK. (2003). Genetics of melanoma predisposition. Oncogene 22: 3053-3062.
15. Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM et al. (2000). Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet 26: 291-299.
16. Jönsson G, Bendahl PO, Sandberg T, Kurbasic A, Staaf J, Sunde L et al. (2005a). Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32. J Natl Cancer Inst 97: 1377-1382.
17. Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR et al. (2005b). Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65: 7612-7621.
18. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. (2003). Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA 100: 1221-1225.
19. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R et al. (2006). Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66: 4182-4190.
20. Macara IG. (2004). Parsing the polarity code. Nat Rev Mol Cell Biol 5: 220-231.
21. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T et al. (2003). Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95: 1878-1890.
22. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, Pellerito S et al. (2006). Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Modern Pathol 19: 616.
23. McLean WH, Irvine AD, Hamill KJ, Whittock NV, Coleman-Campbell CM, Mellerio JE et al. (2003). An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum Mol Genet 12: 2395-2409.
24. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-6488.
25. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-4067.
26. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
27. Pollock PM, Walker GJ, Glendening JM, Que Noy T, Bloch NC, Fountain JW et al. (2002). PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res 12: 565-575.
28. Ren S, Rollins BJ. (2004). Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 117: 239-251.
29. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. (2002). BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 3: software0003.
30. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS et al. (2002). Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62: 3200-3206.
31. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J et al. (2001). Assembly of microarrays for genomewide measurement of DNA copy number. Nat Genet 29: 263-264.
32. Takata M, Goto Y, Ichii N, Yamaura M, Murata H, Koga H et al. (2005). Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J Invest Dermatol 125: 318-322.
33. Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J et al. (2004). Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23: 8796-8804.
34. Tsao H, Goel V, Wu H, Yang G, Haluska FG. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341.
35. Tucker MA, Goldstein AM. (2003). Melanoma etiology: where are we? Oncogene 22: 3042-3052.
36. Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM et al. (2004). Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval. Genes Chromosomes Cancer 41: 56-64.
37. Vance KW, Carreira S, Brosch G, Goding CR. (2005). Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 65: 2260-2268.
38. Zippelius A, Gati A, Bartnick T, Walton S, Odermatt B, Jaeger E et al. (2006). Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother Epub ahead of print.